Registration for a live webinar on 'Neuroleptic malignant syndrome' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
- Epidemiology and risk factors
-
1. Epidemiology of COPD
- Dr. David Mannino
-
2. COPD in never smokers
- Dr. Sundeep Salvi
-
3. Genetics of chronic obstructive pulmonary disease (COPD)
- Prof. Martin Tobin
- Phenotypes of COPD
-
4. COPD and asthma: similarities and differences
- Prof. Peter Barnes
- Pathophysiology and mechanisms of COPD
-
5. The pathology of chronic obstructive pulmonary disease
- Prof. James Hogg
-
6. The continuum of COPD: a physiological perspective
- Prof. Denis O'Donnell
-
7. Inflammatory and immune mechanisms in COPD
- Prof. Peter Barnes
-
8. Mechanisms of COPD exacerbations and relation to exacerbation therapy
- Prof. Wisia Wedzicha
-
9. Protease-antiprotease balance
- Prof. Robert Stockley
- Therapy and management
-
10. Updates in chronic obstructive pulmonary disease (COPD)
- Dr. Omar S. Usmani
-
11. Long-acting bronchodilators in COPD
- Prof. Bart Celli
-
12. Treatment of COPD exacerbations
- Prof. Antonio Anzueto
-
13. Pulmonary rehabilitation: history, promise and problems
- Prof. Richard Casaburi
-
14. Lung volume reduction: advances in COPD
- Dr. Nick Hopkinson
-
15. New pharmacological therapies for COPD
- Prof. Peter Barnes
-
16. The Salford lung study in COPD
- Dr. Dave Leather
- COPD case studies
-
17. COPD treatment case I: COPD with “bronchitis attacks”
- Dr. Janwillem Kocks
-
18. COPD treatment case II: COPD with asthma as child
- Dr. Janwillem Kocks
-
19. COPD treatment case III: COPD with pre-diabetes
- Dr. Janwillem Kocks
-
20. Tailoring care for advanced COPD
- Prof. Wissam Chatila
- Archived Lectures *These may not cover the latest advances in the field
-
21. Alpha-1 antitrypsin deficiency: state of the art
- Dr. Jamie Stoller
-
22. Oxidative stress in COPD
- Prof. William MacNee
-
23. Managing co-morbidity in COPD
- Dr. John Hurst
-
24. Clinical phenotypes of COPD
- Prof. Jørgen Vestbo
-
25. Pulmonary rehabilitation: focusing on rehabilitative exercise
- Prof. Richard Casaburi
-
26. Genetics of COPD
- Prof. Ian Hall
Printable Handouts
Navigable Slide Index
- Introduction
- Outline
- COPD definition - GOLD 2010
- Changes in COPD definition
- Lung function categories
- FEV1/FVC ratio decreases with increasing age
- Lung function in 1000 "COPD" patients
- COPD severity - U.S.
- COPD severity - England
- COPD severity - BOLD
- COPD progression (1)
- COPD progression (2)
- Natural history of chronic airflow obstruction
- What is progression of COPD?
- Diagnosed lung disease & function impairment
- Disease prevalence
- Prevalence of COPD
- Prevalence of COPD 2006 update (1)
- Prevalence of COPD 2006 update (2)
- The PLATINO and BOLD studies
- BOLD sites
- Prevalence of GOLD 2 COPD
- COPD prevalence, by sex, in U.S., 1980-2000
- Decreasing prevalence in Spain?
- No increase in Finland
- Risk of COPD among smokers
- Risk of COPD by age (10 year increase)
- GOLD 2 COPD risk factors: never smoking men
- GOLD 2 COPD risk factors: never smoking women
- Biomass fuel and COPD in China
- Early life exposures (1)
- Early life exposures (2)
- Hospitalizations
- A paradigm of exacerbations (1)
- A paradigm of exacerbations (2)
- COPD exacerbation rate
- COPD hospitalization rate
- End-of-life - disease C (1)
- COPD hospitalizations - U.S. (1980-2000)
- COPD hospitalizations - U.S. (1990-2005)
- Long-term follow-up of U.S. cohorts (1)
- Risk of death following COPD hospitalization
- Long-term follow-up of US cohorts (2)
- Risk of hospitalization
- Mortality
- End-of-life - disease C (2)
- Survival by lung function impairment
- What do COPD patients die from?
- COPD - consequences and comorbidities
- Risk of death within 5 years from baseline
- Mortality following exacerbation
- COPD deaths by sex, race; U.S., 1980 - 2000
- COPD deaths by region; U.S., 1980 - 2000
- Improving survival after COPD hospitalization
- Improving COPD mortality in U.S.
- Conclusions (1)
- Conclusions (2)
- COPD is a preventable and treatable disease
Topics Covered
- GOLD guidelines for COPD
- Lung function categories
- BOLD initiative
- Exacerbation rates for COPD patients
- Hospitalization rates for COPD patients
- Reasons for mortality in COPD patients
- Update interview: An expanded definition of COPD from COPDGene
- Update interview: Key lung function trajectories in the development of COPD
- Update interview: Overlap syndromes with COPD, including asthma, pulmonary fibrosis, obstructive sleep apnea
- Update interview: Combination therapies in the treatment of COPD
- Update interview: Improvement in COPD metrics (hospitalization and mortality)
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Mannino, D. (2021, June 27). Epidemiology of COPD [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved October 13, 2024, from https://doi.org/10.69645/ABBD8833.Export Citation (RIS)
Publication History
Financial Disclosures
- Dr. David Mannino, Consultant: GlaxoSmithKline, Merck, Novartis, Nycomed, Forest; Speaker’s Bureau: Merck, GlaxoSmithKline; Grant/Research Support (Principal Investigator): GlaxoSmithKline, Forest, Boerhinger-Ingelheim.
Update Available
The speaker addresses developments since the publication of the original talk. We recommend listening to the associated update as well as the lecture.
- Full lecture Duration: 30:21 min
- Update interview Duration: 12:43 min
A selection of talks on Clinical Practice
Transcript
Please wait while the transcript is being prepared...
0:00
This is Dr. David Mannino,
professor at the University of Kentucky in Lexington, Kentucky.
Today I will be talking about the epidemiology of COPD.
0:12
These are the topics I'll be reviewing today.
I will start out talking about the various definitions of COPD,
and how they have applied to both disease severity and progression of disease.
I will then discuss various estimates of the prevalence of COPD, and risk factors for COPD.
I will spend the last part of the talk talking about both hospitalizations
and mortality related to COPD, and how these may be changing in recent years.
0:47
The global initiative on chronic obstructive lung disease
(better known as GOLD) has defined COPD in the following way.
The features of this definition include chronic airflow limitation, that is associated
with a number of pathologic changes in the lung.
These will be discussed at length in subsequent talks.
In addition, effects occur outside of the lungs,
along with important comorbid diseases.
This will also be the topic of subsequent talks.
Traditionally the features of COPD have included chronic bronchitis, hallmarked by
cough and sputum production, and emphysema,
which is destruction of the gas-exchanging surfaces of the lungs
(although, as I will discuss in subsequent slides,
the presence of this has become less important in our current definition of COPD).
The changing definition of COPD over the years is noted in this slide.